AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 Department of Hematology, Oncology Center, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 Department of Hematology, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, China
9 Department of Hematology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China
10 Department of Hematology, Tianjin Medical University General Hospital, Tianjin, Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
ABSTRACT
Background
Tyrosine kinase inhibitors combined with immunotherapy have markedly improved outcomes in Ph-positive (Ph+) B-ALL. In contrast, effective, well-tolerated frontline options remain limited for adults with Ph-negative disease. CD22-directed therapy and BCL-2 inhibition have each shown single-agent activity, but data on their rational combination as a chemotherapy-sparing approach are scarce. In this prospective, multicenter phase 2 trial, we evaluated the efficacy of inotuzumab ozogamicin plus venetoclax and examined cytogenetic and MRD correlates of response and survival.
Methods
Eligible patients were previously untreated adults with Ph-negative B-ALL who were aged >60 years or considered unfit for intensive chemotherapy. The AVCDV induction regimen comprised vincristine (1.4 mg/m² on days 1 and 8), cyclophosphamide (150 mg/m² q12h on days 1–3), dexamethasone (20 mg on days 1–4 and 11–14), venetoclax (100 mg on day 6, 200 mg on day 7, and 400 mg on days 8–14), and InO (1 mg on day 4); a second InO dose was permitted on day 15 if bone marrow blasts exceeded 5% on day 14. Response was assessed according to standard criteria by morphology and flow cytometry–based MRD testing with a sensitivity of 0.01%, with ongoing surveillance for relapse. Baseline targeted next-generation sequencing and RNA sequencing were performed for mutation profiling, fusion detection, and expression-based subclassification. Baseline CD22 expression, was descriptively assessed by multiparameter flow cytometry.
Results
Between June 2024 and June 2026, 47 patients were enrolled. The median age was 56 years (range, 18–82), and 24 patients (51.1%) were male. The median white blood cell count was 5.22 × 10?/L (range, 1.17–401.06), reflecting a broad range of baseline disease burden. Baseline genomic profiling identified TP53 mutations in 12 patients (25.5%), KMT2A rearrangements in 5 (10.6%), ZNF384 rearrangements in 5 (10.6%), Ph-like genotype in 4 (8.5%), TCF3::PBX1 in 2 (4.3%), and a complex karyotype in 1 (2.1%).
After AVCDV induction, 46 of 47 patients achieved complete remission (CR; 97.9%), with no treatment-related deaths; 36 of these 46 patients (78.3%) achieved flow cytometric MRD negativity. Among patients with partial CD22 expression at initial immunophenotyping, 5 of 8 (62.5%) achieved MRD negativity. By genetic subgroup, MRD negativity was achieved in 2 of 4 patients (50.0%) with ZNF384 rearrangements, 2 of 4 (50.0%) with Ph-like genotype, and 4 of 5 (80.0%) with KMT2A rearrangements. All patients harboring TCF3::PBX1 and all those with TP53 mutations without concurrent KMT2A rearrangement achieved MRD-negative remission. The response observed in patients with partial CD22 expression supports further evaluation of quantitative CD22 measures, including fluorescence intensity, as potential correlates of response to InO-containing therapy.
At a median follow-up of 9.1 months, the estimated 1-year overall survival and event-free survival rates were 82.1% (95% CI, 67.9–99.3) and 71.0% (95% CI, 55.3–91.0), respectively. In multivariable analysis adjusted for age and white blood cell count, KMT2A rearrangement was independently associated with inferior disease-free survival (HR, 21.10; 95% CI, 3.26–136.37; P=0.001). At the time of last follow-up, no life-threatening adverse events or cases of veno-occlusive disease were observed.
Conclusions
The AVCDV regimen demonstrated promising frontline activity and manageable safety in older or unfit adults with Ph-negative B-ALL across a broad range of baseline disease burden. KMT2A rearrangement remained independently associated with inferior disease-free survival, highlighting the need for alternative strategies in this high-risk subgroup. These findings support further evaluation of MRD- and genotype-adapted treatment approaches and of quantitative CD22 expression and fluorescence intensity measures as potential biomarkers of response to InO-containing regimens.
Trial Registration: ClinicalTrials.gov Identifier: NCT06387121